Gherghe M, Bordea C, Blidaru Al
Chirurgia (Bucur). 2015 Jan-Feb;110(1):26-32.
Identification and biopsy of the sentinel lymph node (SLN) in early-stage breast cancer (T1-T2N0) has become the standard method in the surgical treatment of the axilla, due to its accuracy in the evaluation of axillary lymph node status,thus avoiding extensive axillary lymph node dissection inpatients with negative SLN. The aim of our study is to highlight the role of 99mTc-nanocolloid lymphoscintigraphy in the preoperative lymphatic mapping, especially for SLN localizations outside the axilla, as well as the benefits of this technique in the accurate staging of breast cancer.
430 patients (age 31-81 years) with breast cancer (T1-T2N0 stage) were included in the study group, who underwent lymphoscintigraphy in order to identify the sentinel lymph node in the Nuclear Medicine Department of "Prof. Dr. Al. Trestioreanu" Institute of Oncology, Bucharest,between October 2008 - July 2014. Radiocolloid (99mTc-nanocolloid)was injected using peritumoral or periareolar intradermal technique, doses between 20-37 MBq (0.3-0.5 ml volume), followed by static and dynamic post-injection acquisitions.Intraoperative identification of the SLN was performed using a gamma-probe, guided by the skin marker performed preoperatively after completion of lymphoscintigraphy.
697 sentinel lymph nodes were identified through imaging techniques in 427 patients (99%). Of them, 364 patients had axillary localization of the SLN, while 48 patients(11%) had non-axillary (pectoral, internal mammary, supraclavicular,intra-mammary) localization and 15 patients (3%)had multiple localization (axillary and non-axillary).Intraoperative histopathological exam revealed lymphatic invasion in 74 SLN (12% macrometastases and 88% micrometastases).
The identification and biopsy of the sentinel lymph node in stages I and IIA is a useful routine for accurate breast cancer staging, suited for axillary lymphatic drainage, as well as for unusual non-axillary SLN localization, guiding the clinician for further postoperative management of these patients.
前哨淋巴结(SLN)活检已成为早期乳腺癌(T1-T2N0)腋窝手术治疗的标准方法,因其在评估腋窝淋巴结状态方面具有准确性,从而避免了前哨淋巴结阴性患者进行广泛的腋窝淋巴结清扫。本研究的目的是强调99mTc-纳米胶体淋巴闪烁显像在术前淋巴绘图中的作用,特别是对于腋窝外前哨淋巴结的定位,以及该技术在乳腺癌准确分期中的益处。
430例年龄在31-81岁之间的乳腺癌(T1-T2N0期)患者纳入研究组,于2008年10月至2014年7月期间在布加勒斯特“阿尔.特雷肖雷亚努教授”肿瘤研究所核医学科接受淋巴闪烁显像以确定前哨淋巴结。采用瘤周或乳晕周围皮内注射技术注射放射性胶体(99mTc-纳米胶体),剂量为20-37MBq(体积0.3-0.5ml),随后进行注射后静态和动态采集。术中在前哨淋巴结显像完成后,使用术前皮肤标记引导γ探针进行前哨淋巴结的识别。
通过成像技术在427例患者(99%)中识别出697个前哨淋巴结。其中,364例患者的前哨淋巴结位于腋窝,48例患者(11%)的前哨淋巴结位于非腋窝部位(胸肌、内乳、锁骨上、乳腺内),15例患者(3%)有多个部位(腋窝和非腋窝)的前哨淋巴结。术中组织病理学检查显示74个前哨淋巴结有淋巴浸润(12%为大转移灶,88%为微转移灶)。
I期和IIA期前哨淋巴结的识别和活检是准确进行乳腺癌分期的有用常规方法,适用于腋窝淋巴引流以及不常见的非腋窝前哨淋巴结定位,指导临床医生对这些患者进行进一步的术后管理。